+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Myelofibrosis - Pipeline Insight, 2021

  • ID: 4037127
  • Drug Pipelines
  • March 2021
  • Region: Global
  • 160 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • AstraZeneca
  • Cellenkos
  • Jacobio Pharmaceuticals
  • Novartis
  • Ohm oncology
  • Pharmaxis
  • MORE
This “Myelofibrosis - Pipeline Insight, 2021,” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Myelofibrosis Understanding

Myelofibrosis: Overview

Myelofibrosis is a rare type of blood cancer in which the bone marrow (the soft, spongy tissue inside most bones) is replaced by fibrous scar tissue. It is considered a form of chronic leukemia. When myelofibrosis occurs on its own, it is called as primary myelofibrosis. If the disease occur as the result of a separate disease, it is known as secondary myelofibrosis. For e.g. scar tissue in the bone marrow as a complication of an autoimmune disease. One characteristic of myelofibrosis is the overproduction of giant cells called megakaryocytes. Tests and procedures used to diagnose myelofibrosis include: physical examination, blood tests, imaging tests, bone marrow examination, and gene tests to look for gene mutations in blood cells that are associated with myelofibrosis. Myelofibrosis treatment usually depends on the types of symptoms. Many common Myelofibrosis symptoms are associated with an underlying condition caused by Myelofibrosis, such as anemia or an enlarged spleen. Enlarged spleen related to MF is treated with Radiation therapy, chemotherapy drugs, or surgery. Ruxolitinib (Jakafi) was approved by the U.S. Food and Drug Administration in 2011 to treat the symptoms associated with MF.

"Myelofibrosis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myelofibrosis pipeline landscape is provided which includes the disease overview and Myelofibrosis treatment guidelines. The assessment part of the report embraces, in depth Myelofibrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myelofibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Myelofibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Myelofibrosis.

Myelofibrosis Emerging Drugs Chapters

This segment of the Myelofibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Myelofibrosis Emerging Drugs

Parsaclisib: Incyte Corporation

Parsaclisib (INCB050465) is a potent and selective next-generation PI3Kδ inhibitor that differs in structure from first-generation PI3Kδ inhibitors. The drug is in Phase III clinical evaluation for the treatment of Myelofibrosis.

Selinexor: Karyopharm Therapeutics

Selinexor is an orally administered, small molecule, inhibitor of chromosome region maintenance 1 protein (CRM1). It functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. Selinexor, (XPOVIO), has been approved by the USFDA for relapsed or refractory multiple myeloma, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Selinexor is also currently being evaluated in ongoing Phase 2 and 3 clinical studies in patients with a variety of hematologic and solid tumor malignancies. The drug is in Phase II clinical studies for the treatment of Myelofibrosis.

Myelofibrosis: Therapeutic Assessment

This segment of the report provides insights about the different Myelofibrosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Myelofibrosis

There are approx. 55+ key companies which are developing the therapies for Myelofibrosis. The companies which have their Myelofibrosis drug candidates in the most advanced stage, i.e. Phase III include, Incyte Corporation.

Phases

This report covers around 55+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Myelofibrosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Myelofibrosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myelofibrosis drugs.

Myelofibrosis Report Insights
  • Myelofibrosis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Myelofibrosis Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Myelofibrosis drugs?
  • How many Myelofibrosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myelofibrosis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myelofibrosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Myelofibrosis and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Incyte Corporation
  • Karyopharm Therapeutics
  • Celgene Corporation
  • PharmaEssentia
  • Novartis
  • Secura Bio
  • Pharmaxis
  • Novartis Oncology
  • AstraZeneca
  • Cellenkos
  • Jacobio Pharmaceuticals
  • Ohm oncology
Key Products
  • Parsaclisib
  • Selinexor
  • Lenalidomide
  • Ropeginterferonum alfa-2b
  • Panobinostat
  • PXS-5505
  • Spartalizumab
  • Selumetinib
  • CK-0804
  • JAB-8263
  • OHM-581


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca
  • Cellenkos
  • Jacobio Pharmaceuticals
  • Novartis
  • Ohm oncology
  • Pharmaxis
  • MORE
Introduction

Executive Summary

Myelofibrosis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Myelofibrosis - Analytical Perspective

In-depth Commercial Assessment
  • Myelofibrosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Myelofibrosis Collaboration Deals
  • Company-Company Collaborations (Licensing/Partnering) Analysis
  • Company-University Collaborations (Licensing/Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Parsaclisib: Incyte Corporation
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Selinexor: Karyopharm Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I/II)
  • Comparative Analysis
PXS-5505: Pharmaxis
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical and Discovery Stage Products
  • Comparative Analysis
CK-0804: Cellenkos
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Myelofibrosis Key Companies

Myelofibrosis Key Products

Myelofibrosis- Unmet Needs

Myelofibrosis- Market Drivers and Barriers

Myelofibrosis- Future Perspectives and Conclusion

Myelofibrosis Analyst Views

Myelofibrosis Key Companies

Appendix

List of Tables
Table 1 Total Products for Myelofibrosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Myelofibrosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
3 of 3
  • Incyte Corporation
  • Karyopharm Therapeutics
  • Celgene Corporation
  • PharmaEssentia
  • Novartis
  • Secura Bio
  • Pharmaxis
  • Novartis Oncology
  • AstraZeneca
  • Cellenkos
  • Jacobio Pharmaceuticals
  • Ohm oncology
Note: Product cover images may vary from those shown
Adroll
adroll